In the heart of the science and business location Heidelberg, GeneWerk GmbH has found ideal conditions for steady growth. For six years, the company with its experienced and motivated staff has been offering NGS-based molecular biological analysis services, especially for companies in the pharmaceutical, life sciences and biotechnology industries. The aim is to advance the development of innovative therapies such as gene and immunotherapies through comprehensive safety analyses. Safe and effective therapies are thus within reach for many diseases. In addition to pure research contracts and preclinical testing, the analyses also include examinations of patient material as part of clinical trials. In particular, the guidelines of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) must be observed. Through the merger with Protagen Protein Services GmbH, GeneWerk was able to expand its portfolio to include protein characterisation, identity, purity, potency and capsid loading to become a full-service partner for the development of novel therapies by the biopharmaceutical industry.